40 related articles for article (PubMed ID: 31983622)
1. Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
Chou LP; Hsu CW; Yang SF; Lee CT; Ou YC; Lin KC; Hu CY; Jou YC; Tsai YS; Chow NH
Clin Genitourin Cancer; 2023 Aug; 21(4):508.e1-508.e10. PubMed ID: 37183125
[TBL] [Abstract][Full Text] [Related]
2. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
Cox A; Klümper N; Stein J; Sikic D; Breyer J; Bolenz C; Roghmann F; Erben P; Wirtz RM; Wullich B; Ritter M; Hölzel M; Schwamborn K; Horn T; Gschwend J; Hartmann A; Weichert W; Erlmeier F; Eckstein M
Eur Urol; 2024 Apr; 85(4):328-332. PubMed ID: 37031005
[TBL] [Abstract][Full Text] [Related]
3. Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report.
Shang P; Lou C; Yin L; Tao C; Dong Y; Yang G; Yuan Z
J Int Med Res; 2023 Nov; 51(11):3000605231204502. PubMed ID: 37917812
[TBL] [Abstract][Full Text] [Related]
4. Upper Urothelial Tract Extraosseous Bone Formation: An Unexpected Finding and Differential Diagnostic Considerations.
Potterveld SK; Wang N; Sangoi AR
Int J Surg Pathol; 2024 Jan; ():10668969231221755. PubMed ID: 38298018
[TBL] [Abstract][Full Text] [Related]
5. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.
Patelli G; Zeppellini A; Spina F; Righetti E; Stabile S; Amatu A; Tosi F; Ghezzi S; Siena S; Sartore-Bianchi A
Cancer Treat Rev; 2022 Mar; 104():102351. PubMed ID: 35180563
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
7. How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
Conci N; Tassinari E; Tateo V; Rosellini M; Marchetti A; Ricci C; Chessa F; Santoni M; Grande E; Mollica V; Massari F
Mol Diagn Ther; 2024 Jan; 28(1):37-51. PubMed ID: 37874465
[TBL] [Abstract][Full Text] [Related]
8.
Zimpfer A; Kdimati S; Mosig M; Rudolf H; Zettl H; Erbersdobler A; Hakenberg OW; Maruschke M; Schneider B
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173881
[TBL] [Abstract][Full Text] [Related]
9. Prognostic analysis of inflammatory response-related genes and biomarkers in patients with urothelial carcinoma of ureter.
Chen H; Liu S; Li X; Wang Z; Zhang C
Front Genet; 2023; 14():1139412. PubMed ID: 36936427
[TBL] [Abstract][Full Text] [Related]
10. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
[TBL] [Abstract][Full Text] [Related]
11. HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
Sanguedolce F; Zanelli M; Palicelli A; Bisagni A; Zizzo M; Ascani S; Pedicillo MC; Cormio A; Falagario UG; Carrieri G; Cormio L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835131
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
13. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
[TBL] [Abstract][Full Text] [Related]
14. HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
Yorozu T; Sato S; Kimura T; Iwatani K; Onuma H; Yanagisawa T; Miki J; Egawa S; Ikegami M; Takahashi H
Clin Genitourin Cancer; 2020 Aug; 18(4):e443-e449. PubMed ID: 31983622
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.
Ehsani L; Osunkoya AO
Int J Clin Exp Pathol; 2014; 7(5):2544-50. PubMed ID: 24966967
[TBL] [Abstract][Full Text] [Related]
17. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma.
Williams AK; Kassouf W; Chin J; Rendon R; Jacobsen N; Fairey A; Kapoor A; Black P; Lacombe L; Tanguay S; So A; Lattouf JB; Bell D; Fradet Y; Saad F; Matsumoto E; Drachenberg D; Cagiannos I; Izawa JI
Urol Oncol; 2013 Oct; 31(7):1161-5. PubMed ID: 23415596
[TBL] [Abstract][Full Text] [Related]
18. Pathology and staging of urothelial tumors of the kidney and ureter.
Melamed MR; Reuter VE
Urol Clin North Am; 1993 May; 20(2):333-47. PubMed ID: 8388136
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
